CLSA has released a research report stating that Pharmaron (03759, 300759.SZ) has revised its 2025 revenue growth guidance from 10%-15% year-on-year to 12%-16%, with adjusted non-IFRS net profit expected to achieve double-digit growth. The firm views the upward revision of guidance and increased backlog as positive indicators for the fourth quarter of this year through next year. CLSA has raised its revenue and net profit forecasts for Pharmaron from 2025 to 2027, increasing the H-share target price from HK$24.7 to HK$28.8 and the A-share target price from RMB 34.8 to RMB 40.6, maintaining an "Outperform" rating for both.